InfertilityPhase 1Celestial-2NCT06511791
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.
A Phase 1 study testing FE 999302 and Follitropin delta in people with Infertility, run by Ferring Pharmaceuticals at 15 sites in 5 countries.
Trial summary
This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle). The trial is a randomised, double blind, placebo controlled, parallel group, exploratory trial, investigating the effect of FE 999302 when administered during different time intervals in women undergoing… Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Infertility
- What is being tested?
- FE 999302 and Follitropin delta
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 106 participants
- Where
- 15 sitesin 5 countries
- Study dates
- 15 Jul 2024to 16 Oct 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Subject informed consent form signed before any trial-related activities.
- In good physical and mental health as judged by the investigator.
- Serum anti-Müllerian hormone (AMH) levels of >35.0 pmol/L at screening (measured at central laboratory).
- Pre-menopausal women between the ages of 18 and 40 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 40 years (up to the day before the 41st birthday) when they sign the informed consent(s).
- Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
- Infertility for at least 1 year before screening for subjects <35 years or for at least 6 months for subjects ≥35 years (not applicable in case of tubal or severe male factor infertility).
Show all 10Show fewer
- No more than two controlled ovarian stimulation cycles initiated, regardless of outcome (taking exclusion criteria 2 and 3 into account) and the subject must be suitable for treatment with 10 or 15 µg/day follitropin delta (corresponding to 150 or 225 IU).
- Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
- Early follicular phase (cycle day 2-5) serum levels of follicle-stimulating hormone (FSH) between 1 and 15 IU/L (measured at central laboratory).
- Body mass index (BMI) between 18.0 and 32.0 kg/m2 (both inclusive) at screening.
Who cannot join
- Known polycystic ovary syndrome (PCOS) or known endometriosis stage III-IV (American Society for Reproductive Medicine, 2012).
- Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day (corresponding to 10 µg follitropin delta) or higher. Poor response is defined as <4 oocytes retrieved, or cycle cancellation before oocyte retrieval due to inadequate follicular development.
- Severe ovarian hyperstimulation syndrome (OHSS; grade 4 or 5) in a previous controlled ovarian stimulation cycle, as judged by the investigator.
- One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound before randomisation on stimulation day 1 (puncture of cysts is allowed before randomisation).
- Any known clinically significant systemic disease (e.g. insulin-dependent diabetes).
- Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver, or kidney) with the exception of controlled thyroid function disease.
Show all 13Show fewer
- Known tumours of the ovary, breast, uterus, adrenal gland, pituitary, or hypothalamus which would contraindicate the use of gonadotropins.
- Any abnormal finding of clinical chemistry and haematology at screening or vital signs at randomisation, which is judged clinically relevant by the investigator and/or requires intervention.
- Currently breast-feeding.
- Undiagnosed vaginal bleeding.
- Findings at the gynaecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device.
- Pregnancy (negative urinary pregnancy tests must be documented at screening and before randomisation) or contraindication to pregnancy.
- Use of fertility modifiers during the last menstrual cycle before screening, including dehydroepiandrosterone (DHEA) and metformin or cycle programming with oral contraceptives, progestogen, or estrogen preparations.
Trial locations and contacts
15 sites in 5 countries.
15 sites in 5 countries
Spain5 sites
Ferring Investigational Site
Barcelona, 08028
Ferring Investigational Site
Madrid, 28010
Ferring Investigational Site
Madrid, 28023
Ferring Investigational Site
Seville, 41092
Ferring Investigational Site
Valencia, 46015
Czechia3 sites
Ferring Investigational Site
Prague, 150 00
Ferring Investigational Site
Prague, 16000
Ferring Investigational Site
Prague, 184 00
Norway3 sites
Ferring Investigational Site
Bergen, 5006
Ferring Investigational Site
Porsgrunn, 3913
Ferring Investigational Site
Trondheim, 7042
Belgium2 sites
Ferring Investigational Site
Brussels, 1090
Ferring Investigational Site
Edegem, 2650
Denmark2 sites
Ferring Investigational Site
Copenhagen, 2100
Ferring Investigational Site
Hvidovre, 2650
About this study
Official title: A Randomised, Double-blind, Placebo-controlled, Parallel-group Exploratory Trial to Investigate the Effect of FE 999302 When Administered During Different Time Intervals in Women Undergoing Controlled Ovarian Stimulation With a Fixed Dose of Follitropin Delta in a Gonadotropin-releasing Hormone Antagonist Protocol.
This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle). The trial is a randomised, double blind, placebo controlled, parallel group, exploratory trial, investigating the effect of FE 999302 when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a antagonist protocol.
Read the detailed description
The trial is multicentre, randomized, partially double-blind, placebo-controlled, parallel-group investigating the effect of FE999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
The primary endpoint is the number of good-quality blastocysts on day 5 after oocyte retrieval. Secondary endpoints are number of follicles by size category and serum concentration of different hormones on stimulation day 6 and end-of stimulation, the number of stimulation days and oocytes retrieved, the number of metaphase II oocytes and fertilised oocytes, number of blastocysts on day 5, number of cryopreserved blastocysts, endometrial thickness at eos, positive bhcg rate, clinical pregnancy, vital pregnancy and ongoing pregnancy.
- Conditions
- Infertility
- Being tested
- FE 999302, Follitropin delta, Placebo FE 999302
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FE 999302Drug
Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
Follitropin deltaDrug
Also called REKOVELLE
The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
Placebo FE 999302Drug
No active ingredient, subcutaneous injection.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Group | Placebo comparator | Placebo from day 1 to end of stimulation Receives: Drug: Follitropin delta; Drug: Placebo FE 999302 |
| FE 999302 Group | Active comparator | FE 999302 from stimulation day 1 to end-of-stimulation Receives: Drug: FE 999302; Drug: Follitropin delta |
| FE 999302 and Placebo Group | Active comparator | FE 999302 from stimulation day 1 to stimulation day 5, and placebo stimulation day 6 to end-of-stimulation Receives: Drug: FE 999302; Drug: Follitropin delta; Drug: Placebo FE 999302 |
| Placebo and FE 999302 | Active comparator | Placebo from stimulation day 1 to stimulation 5, FE 999302 from stimulation day 6 to end-of-stimulation. Receives: Drug: FE 999302; Drug: Follitropin delta; Drug: Placebo FE 999302 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of good-quality blastocysts
Number of good-quality blastocysts on day 5 after oocyte retrieval
Measured: Day 5
Secondary outcomes (13)
Number and Size of Follicles
Number of follicles by size category on stimulation day 5 and at end-of-stimulation
Measured: Day 5 and up to 20 days
Serum hormone concentrations
Serum hormone concentrations of progesterone, androstenedione, estradiol, inhibin B, and luteinising hormone (LH).
Measured: Day 5, up to 20 days, and up to 22 days
Number of Stimulation Days
Number of stimulation days
Measured: Up to 20 days
Number of Oocytes
Number of oocytes retrieved
Measured: Up to 22 days
Number of metaphase II oocytes
Number of metaphase II (MII) oocytes
Measured: Up to 22 days
Number of fertilised oocytes
Number of fertilised (2 pronuclei [2PN]) oocytes
Measured: Up to 22 days
Number of blastocysts
Number of blastocysts
Measured: Up to 27 days
Number of cryopreserved blastocysts
Number of cryopreserved blastocysts
Measured: Up to 28 days
Endometrial thickness
Endometrial thickness
Measured: Up to 20 days and up to 27 days
Positive βhCG
Positive βhCG
Measured: 13-15 days after fresh transfer
Clinical pregnancy
Clinical pregnancy measured by at least one gestational sac 5-6 weeks after fresh transfer
Measured: 5-6 weeks after fresh transfer
Vital pregnancy
Vital pregnancy measured by at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after fresh transfer
Measured: 5-6 weeks after fresh transfer
Ongoing pregnancy
Ongoing pregnancy measured by at least one intrauterine viable fetus 10-11 weeks after fresh transfer
Measured: 10-11 weeks after fresh transfer
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2024
- Study start15 Jul 2024
- Primary completion16 Oct 2025
- Study completion16 Oct 2025
Why it stopped: This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 106 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ferring Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ferring Pharmaceuticals, Study director, Ferring Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06511791
- Sponsor's protocol ID
- 000427
- Other IDs
- 2023-508149-42-00, 2023
- Acronym
- Celestial-2
- Status last verified
- Mar 2026
- First submitted
- 8 Jul 2024
- Last updated
- 30 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Exploratory Trial to Investigate the Effect of FE 999302 When Administered During Different Time Intervals in Women Undergoing Controlled Ovarian Stimulation With a Fixed Dose of Follitropin Delta in a Gonadotropin-releasing Hormone Antagonist Protocol.
- ClinicalTrials.gov ID
- NCT06511791
- Acronym / sponsor ID
- Celestial-2 / 000427
- Conditions
- Infertility
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.
- Enrolment
- 106 participants (actual)
- Lead sponsor
- Ferring PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 15 Jul 2024 (actual)
- Primary completion
- 16 Oct 2025 (actual)
- Study completion
- 16 Oct 2025 (actual)
- First posted
- 22 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle). The trial is a randomised, double blind, placebo controlled, parallel group, exploratory trial, investigating the effect of FE 999302 when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a antagonist protocol.
Detailed description
The trial is multicentre, randomized, partially double-blind, placebo-controlled, parallel-group investigating the effect of FE999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
The primary endpoint is the number of good-quality blastocysts on day 5 after oocyte retrieval. Secondary endpoints are number of follicles by size category and serum concentration of different hormones on stimulation day 6 and end-of stimulation, the number of stimulation days and oocytes retrieved, the number of metaphase II oocytes and fertilised oocytes, number of blastocysts on day 5, number of cryopreserved blastocysts, endometrial thickness at eos, positive bhcg rate, clinical pregnancy, vital pregnancy and ongoing pregnancy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo Group | Placebo comparator | Drug: Follitropin delta, Drug: Placebo FE 999302Placebo from day 1 to end of stimulation |
| FE 999302 Group | Active comparator | Drug: FE 999302, Drug: Follitropin deltaFE 999302 from stimulation day 1 to end-of-stimulation |
| FE 999302 and Placebo Group | Active comparator | Drug: FE 999302, Drug: Follitropin delta, Drug: Placebo FE 999302FE 999302 from stimulation day 1 to stimulation day 5, and placebo stimulation day 6 to end-of-stimulation |
| Placebo and FE 999302 | Active comparator | Drug: FE 999302, Drug: Follitropin delta, Drug: Placebo FE 999302Placebo from stimulation day 1 to stimulation 5, FE 999302 from stimulation day 6 to end-of-stimulation. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Subject informed consent form signed before any trial-related activities.
- In good physical and mental health as judged by the investigator.
- Serum anti-Müllerian hormone (AMH) levels of >35.0 pmol/L at screening (measured at central laboratory).
- Pre-menopausal women between the ages of 18 and 40 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 40 years (up to the day before the 41st birthday) when they sign the informed consent(s).
- Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
Key exclusion criteria (13 listed)
- Known polycystic ovary syndrome (PCOS) or known endometriosis stage III-IV (American Society for Reproductive Medicine, 2012).
- Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day (corresponding to 10 µg follitropin delta) or higher. Poor response is defined as <4 oocytes retrieved, or cycle cancellation before oocyte retrieval due to inadequate follicular development.
- Severe ovarian hyperstimulation syndrome (OHSS; grade 4 or 5) in a previous controlled ovarian stimulation cycle, as judged by the investigator.
- One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound before randomisation on stimulation day 1 (puncture of cysts is allowed before randomisation).
- Any known clinically significant systemic disease (e.g. insulin-dependent diabetes).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FE 999302Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol | Drug | FE 999302 Group, FE 999302 and Placebo Group, Placebo and FE 999302 |
| Follitropin deltaAlso: REKOVELLEThe effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin. | Drug | FE 999302 Group, FE 999302 and Placebo Group, Placebo Group, Placebo and FE 999302 |
| Placebo FE 999302No active ingredient, subcutaneous injection. | Drug | FE 999302 and Placebo Group, Placebo Group, Placebo and FE 999302 |
Primary outcome
Number of good-quality blastocysts
Time frame: Day 5
Number of good-quality blastocysts on day 5 after oocyte retrieval
13 secondary outcomes
Number and Size of Follicles
Time frame: Day 5 and up to 20 days
Serum hormone concentrations
Time frame: Day 5, up to 20 days, and up to 22 days
Number of Stimulation Days
Time frame: Up to 20 days
Number of Oocytes
Time frame: Up to 22 days
Number of metaphase II oocytes
Time frame: Up to 22 days
Number of fertilised oocytes
Time frame: Up to 22 days
Number of blastocysts
Time frame: Up to 27 days
Number of cryopreserved blastocysts
Time frame: Up to 28 days
Endometrial thickness
Time frame: Up to 20 days and up to 27 days
Positive βhCG
Time frame: 13-15 days after fresh transfer
Clinical pregnancy
Time frame: 5-6 weeks after fresh transfer
Vital pregnancy
Time frame: 5-6 weeks after fresh transfer
Ongoing pregnancy
Time frame: 10-11 weeks after fresh transfer
Results and safety
The study was stopped early (reason given: This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ferring Pharmaceuticals study director
Ferring Pharmaceuticals
15 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing FE 999302 and Follitropin delta in people with Infertility, run by Ferring Pharmaceuticals at 15 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in Spain, Czechia, Norway, Belgium, Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of good-quality blastocysts (time frame: Day 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.